Skip to main content

Vertex Pharmaceuticals balance sheet

  • VRTX · Nasdaq
  • Pharmaceuticals
  • Biotechnology
  • S&P 500
$538.60−0.74%Close 13 Nov 2026

At the end of fiscal 2025 (the year to 31 Dec 2025), Vertex Pharmaceuticals reported total assets of $25.64B, $5.08B in cash and equivalents, $1.92B of total debt; shareholders' equity was $18.67B.

From Vertex Pharmaceuticals's annual and quarterly reports, each period checked against accounting identities; a figure that does not pass is left blank. Fiscal years follow the company's calendar, the latest ending 31 Dec 2025.

Annual

Vertex Pharmaceuticals balance sheet, annual
USDFY 2008FY 2009FY 2010FY 2011FY 2012FY 2013FY 2014FY 2015FY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
Cash and equivalents$389.1M$446.7M$243.2M$475.3M$489.4M$569.3M$625.3M$714.8M$1.18B$1.67B$2.65B$3.11B$5.99B$6.79B$10.50B$10.37B$4.57B$5.08B
Short-term investments—$838.3M$788.2M$493.6M$831.8M$895.8M$761.8M$327.7M$250.6M$423.3M$518.1M$699.0M$670.7M$729.9M$274.5M$849.2M$1.55B$1.52B
Cash and short-term investments$389.1M$1.28B$1.03B$968.9M$1.32B$1.47B$1.39B$1.04B$1.43B$2.09B$3.17B$3.81B$6.66B$7.52B$10.78B$11.22B$6.12B$6.61B
Accounts receivable—$9.60M$12.53M$183.1M$143.3M$85.52M$75.96M$173.8M$200.4M$281.3M$409.7M$633.5M$885.4M$1.14B$1.44B$1.56B$1.61B$2.05B
Inventory———$112.4M$30.46M$14.15M$30.85M$57.21M$77.60M$111.8M$124.4M$167.5M$280.8M$353.1M$460.6M$738.8M$1.21B$1.69B
Current assets—$1.31B$1.06B$1.33B$1.59B$1.59B$1.55B$1.41B$1.83B$2.65B$3.84B$4.82B$8.13B$9.56B$13.23B$14.14B$9.60B$11.20B
Property, plant and equipment—$62.28M$72.33M$133.2M$433.6M$696.9M$715.8M$697.7M$698.4M$789.4M$812.0M$745.1M——————
Goodwill—$26.10M$26.10M$30.99M$30.99M$30.99M$39.91M$50.38M$50.38M$50.38M$50.38M$1.00B$1.00B$1.00B$1.09B$1.09B$1.09B$1.09B
Acquired intangibles——————————$0.00$400.0M$400.0M$400.0M$603.6M$839.9M$825.9M$424.2M
Long-term investments——————————————$112.2M$2.50B$5.11B$5.71B
Total assets—$1.96B$1.73B$2.20B$2.76B$2.32B$2.33B$2.50B$2.90B$3.55B$6.25B$8.32B$11.75B$13.43B$18.15B$22.73B$22.53B$25.64B
Accounts payable—$36.99M$35.85M$74.64M$101.3M$49.33M$71.19M$74.94M$61.45M$73.99M$111.0M$87.61M$155.1M$195.0M$303.9M$364.9M$413.0M$461.7M
Unearned revenue, current—$74.96M$74.62M$45.04M$27.57M$21.51M$17.47M$16.30M$6.00M$5.17M————————
Long-term debt · current portion—————————————————$0.00
Current liabilities—$284.9M$474.8M$392.3M$432.6M$397.8M$368.3M$506.2M$792.5M$807.3M$1.12B$1.33B$1.88B$2.14B$2.74B$3.55B$3.56B$3.86B
Long-term debt · non-current—————————————————$0.00
Operating lease liability———————————$95.80M$361.0M$410.7M$428.1M$381.7M$1.63B$1.92B
Finance lease liability——————————$596.6M$577.4M$581.5M$556.7M$471.6M$426.7M$118.0M$112.2M
Total liabilities—$859.1M$1.22B$1.24B$1.52B$962.6M$1.24B$1.40B$1.56B$1.50B$1.81B$2.23B$3.06B$3.33B$4.24B$5.15B$6.12B$6.98B
Retained earnings—−$2.69B−$3.44B−$3.41B−$3.52B−$3.97B−$4.71B−$5.26B−$5.37B−$5.12B−$2.99B−$1.85B$858.7M$3.20B$6.52B$10.14B$9.61B$13.56B
Minority interest———$141.6M$196.7M$0.00$21.18M$153.7M$181.6M$13.73M$0.00———————
Shareholders' equity$238.9M$1.10B$504.0M$786.8M$999.2M$1.36B$1.08B$940.0M$1.16B$2.03B$4.44B$6.09B$8.69B$10.10B$13.91B$17.58B$16.41B$18.67B
Total liabilities and equity—$1.96B$1.73B$2.20B$2.76B$2.32B$2.33B$2.50B$2.90B$3.55B$6.25B$8.32B$11.75B$13.43B$18.15B$22.73B$22.53B$25.64B
Total debt———————$295.2M$300.0M—$596.6M$673.2M$942.5M$967.4M$899.7M$808.4M$1.75B$1.92B
Net debt———————−$747.3M−$1.13B—−$2.57B−$3.14B−$5.72B−$6.56B−$9.88B−$10.41B−$4.37B−$4.68B
Net working capital—$575.5M$339.1M$463.6M$667.6M$621.4M$553.0M$186.2M−$144.9M$176.3M$72.68M$378.7M$267.7M$623.6M−$11.30M$227.7M$1.46B$2.25B
Shares outstanding · period end—200M204M209M217M234M242M246M248M253M255M259M260M254M257M258M257M254M

Quarterly

Vertex Pharmaceuticals balance sheet, quarterly
USDQ4 FY2023Q1 FY2024Q2 FY2024Q3 FY2024Q4 FY2024Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026
Cash and equivalents$10.37B$9.16B$4.58B$5.24B$4.57B$4.67B$4.97B$4.94B$5.08B$5.49B$6.14B$4.98B
Short-term investments$849.2M$1.01B$1.22B$1.29B$1.55B$1.53B$1.41B$1.35B$1.52B$1.75B$1.71B$1.32B
Cash and short-term investments$11.22B$10.17B$5.80B$6.52B$6.12B$6.20B$6.38B$6.29B$6.61B$7.25B$7.85B$6.30B
Accounts receivable$1.56B$1.79B$1.66B$1.75B$1.61B$1.81B$1.89B$1.95B$2.05B$2.00B$2.13B$2.31B
Inventory$738.8M$813.1M$914.6M$1.08B$1.21B$1.36B$1.50B$1.63B$1.69B$1.77B$1.77B$2.25B
Current assets$14.14B$13.29B$8.94B$9.80B$9.60B$10.01B$10.43B$10.57B$11.20B$11.73B$12.54B$11.69B
Goodwill$1.09B$1.09B$1.09B$1.09B$1.09B$1.09B$1.09B$1.09B$1.09B$1.09B$1.09B$2.42B
Acquired intangibles$839.9M$834.9M$837.5M$831.6M$825.9M$441.2M$435.5M$429.8M$424.2M$418.5M$412.8M$8.52B
Long-term investments$2.50B$4.38B$4.39B$4.70B$5.11B$5.16B$5.65B$5.72B$5.71B$5.75B$5.79B$3.52B
Total assets$22.73B$23.92B$20.13B$22.24B$22.53B$22.88B$24.04B$24.86B$25.64B$26.48B$27.42B$32.74B
Accounts payable$364.9M$351.4M$327.9M$395.8M$413.0M$445.0M$442.3M$420.3M$461.7M$489.3M$429.5M$472.6M
Long-term debt · current portion————————$0.00——$999.6M
Current liabilities$3.55B$3.80B$3.55B$3.97B$3.56B$3.78B$4.14B$4.48B$3.86B$3.88B$3.94B$5.00B
Long-term debt · non-current————————$0.00——$3.50B
Operating lease liability$381.7M——$1.66B$1.63B———$1.92B———
Finance lease liability$426.7M——$119.1M$118.0M———$112.2M———
Total liabilities$5.15B$5.37B$5.36B$6.61B$6.12B$6.38B$6.86B$7.54B$6.98B$7.12B$7.18B$11.83B
Retained earnings$10.14B$11.24B$7.65B$8.69B$9.61B$10.25B$11.29B$12.37B$13.56B$14.59B$15.69B$16.34B
Shareholders' equity$17.58B$18.55B$14.77B$15.63B$16.41B$16.50B$17.18B$17.32B$18.67B$19.36B$20.25B$20.91B
Total liabilities and equity$22.73B$23.92B$20.13B$22.24B$22.53B$22.88B$24.04B$24.86B$25.64B$26.48B$27.42B$32.74B
Total debt$808.4M$721.3M$933.4M$1.77B$1.75B$1.66B$1.53B$1.83B$1.92B$1.99B$1.98B$6.48B
Net debt−$10.41B−$9.45B−$4.86B−$4.75B−$4.37B−$4.55B−$4.86B−$4.45B−$4.68B−$5.26B−$5.87B$175.1M
Net working capital$227.7M$334.8M$814.3M$591.8M$1.46B$1.55B$1.32B$1.15B$2.25B$2.36B$2.46B$1.71B
Shares outstanding · period end258M258M258M258M257M257M256M254M254M254M253M254M

The main figures as JSON and plain text. See data and methodology.

VRTX in the terminal

Every line back twenty years, charts of any figure, segments and KPIs by quarter, valuation and alerts.